{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:16:15Z","timestamp":1784740575404,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.tmrv.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:47:12Z","timestamp":1663807632000},"page":"204-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP)"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-9634","authenticated-orcid":false,"given":"Melissa","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.tmrv.2022.09.001_bib0001","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0002","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"10.1016\/j.tmrv.2022.09.001_bib0003","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.tmrv.2022.09.001_bib0004","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"van Dorland","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2022.09.001_bib0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0006","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.tmrv.2022.09.001_bib0007","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/bloodadvances.2022007025","article-title":"Alterations in B- and circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Shin","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0008","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.tmrv.2022.09.001_bib0009","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.tmrv.2022.09.001_bib0010","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0012","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1016\/j.tmrv.2022.09.001_bib0013","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1182\/blood.V118.21.3299.3299","article-title":"Anti-ADAMTS13 inhibitor boosting during plasma exchange therapy in acquired TTP Is the expression of a general dysregulation of the immune response","volume":"118","author":"Schaller","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tmrv.2022.09.001_bib0014","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.tmrv.2022.09.001_bib0015","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood-2016-04-710475","article-title":"Adjuvant rituximab to prevent TTP relapse","volume":"127","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.tmrv.2022.09.001_bib0016","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tmrv.2022.09.001_bib0017","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0018","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2008","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0019","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.tmrv.2022.09.001_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002770050549","article-title":"Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura","volume":"78","author":"Ferrara","year":"1999","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.tmrv.2022.09.001_bib0021","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0609.2007.00832.x","article-title":"Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura","volume":"78","author":"Ahmad","year":"2007","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0022","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2141.2006.06384.x","article-title":"An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"136","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.tmrv.2022.09.001_bib0023","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0024","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/asheducation-2015.1.637","article-title":"Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange","volume":"2015","author":"Coppo","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/asheducation-2018.1.539","article-title":"Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura","volume":"2018","author":"Dane","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0026","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s11239-015-1259-6","article-title":"The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura","volume":"41","author":"Rottenstreich","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.tmrv.2022.09.001_bib0027","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0028","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13408","article-title":"A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed\/refractory thrombotic thrombocytopenic purpura treated with rituximab","volume":"170","author":"Clark","year":"2015","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.tmrv.2022.09.001_bib0029","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0031","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0032","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tmrv.2022.09.001_bib0033","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10787-021-00863-2","article-title":"Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases","volume":"29","author":"Khalesi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.tmrv.2022.09.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211046428","article-title":"Bortezomib in autoimmune hemolytic anemia and beyond","volume":"12","author":"Pasquale","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1016\/j.tmrv.2022.09.001_bib0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.tmrv.2022.09.001_bib0036","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.tmrv.2022.09.001_bib0037","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.tmrv.2022.09.001_bib0038","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","author":"Hartono","year":"2014","journal-title":"J Nephrol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.tmrv.2022.09.001_bib0041","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"issue":"16","key":"10.1016\/j.tmrv.2022.09.001_bib0042","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1182\/blood-2011-09-377754","article-title":"The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells","volume":"119","author":"Sorvillo","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.tmrv.2022.09.001_bib0043","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJMc1301264","article-title":"Antibody depletion by bortezomib through blocking of antigen presentation","volume":"368","author":"Park","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0044","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses essential immune functions of human CD4+ T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0045","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0046","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.tmrv.2022.09.001_bib0047","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl Cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.tmrv.2022.09.001_bib0048","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"De Weers","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0049","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"21","key":"10.1016\/j.tmrv.2022.09.001_bib0050","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood.V120.21.2974.2974","article-title":"Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking","volume":"120","author":"Marco Jansen","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.tmrv.2022.09.001_bib0051","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tmrv.2022.09.001_bib0052","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.tmrv.2022.09.001_bib0053","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04063-w","article-title":"Daratumumab for refractory warm autoimmune hemolytic anemia","volume":"100","author":"Jain","year":"2021","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0054","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.tmrv.2022.09.001_bib0055","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0056","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/trf.13465","article-title":"Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib","volume":"56","author":"Patel","year":"2016","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.tmrv.2022.09.001_bib0057","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura","volume":"6","author":"van den Berg","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0058","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjh.12696","article-title":"Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura","volume":"164","author":"Mazepa","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0059","doi-asserted-by":"crossref","first-page":"e28818","DOI":"10.1002\/pbc.28818","article-title":"Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases","volume":"68","author":"Maschan","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.tmrv.2022.09.001_bib0060","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0061","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/imj.13804","article-title":"Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand","volume":"48","author":"Fox","year":"2018","journal-title":"Intern. Med. J"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0062","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5482\/HAMO-12-10-0016","article-title":"The Oklahoma thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome registry. a model for clinical research, education and patient care","volume":"33","author":"George","year":"2013","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.tmrv.2022.09.001_bib0063","series-title":"Thrombotic microangiopathies (TMA) registry Australia","year":"2022"},{"issue":"21","key":"10.1016\/j.tmrv.2022.09.001_bib0064","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.transci.2019.02.003","article-title":"Refractory thrombotic thrombocytopenic purpura in a patient with Kaposi sarcoma","volume":"58","author":"Sahin","year":"2019","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0066","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/trf.16117","article-title":"Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy","volume":"61","author":"Lancelot","year":"2021","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0067","doi-asserted-by":"crossref","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0068","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40959-017-0023-9","article-title":"Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma","volume":"3","author":"Chen","year":"2017","journal-title":"Cardio-Oncology"},{"issue":"3","key":"10.1016\/j.tmrv.2022.09.001_bib0069","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.tmrv.2022.09.001_bib0070","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/art.33333","article-title":"Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells","volume":"64","author":"Ichikawa","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0071","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.intimp.2011.11.019","article-title":"Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE","volume":"12","author":"Seavey","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.tmrv.2022.09.001_bib0072","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.tmrv.2022.09.001_bib0073","article-title":"Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib","volume":"2018","author":"Atallah-Yunes","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0074","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.tmrv.2022.09.001_bib0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.tmrv.2022.09.001_bib0076","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s10067-022-06155-6","article-title":"Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review","volume":"41","author":"Liang","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.09.001_bib0077","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ejh.12206","article-title":"Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib","volume":"92","author":"van Balen","year":"2014","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.tmrv.2022.09.001_bib0078","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.09.001_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215491","article-title":"Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura","volume":"2016","author":"Acedillo","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.tmrv.2022.09.001_bib0080","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2022.09.001_bib0081","first-page":"9681832","article-title":"Remission of severe, relapsed, and refractory TTP after multiple cycles of bortezomib","volume":"2017","author":"Pandey","year":"2017","journal-title":"Case Rep Hematol"},{"issue":"43","key":"10.1016\/j.tmrv.2022.09.001_bib0082","doi-asserted-by":"crossref","first-page":"e12989","DOI":"10.1097\/MD.0000000000012989","article-title":"Relapsed\/refractory acquired thrombotic thrombocytopenic purpura in a patient with Sj\u00f6gren syndrome: Case report and review of the literature","volume":"97","author":"Sun","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0083","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.medcli.2018.06.002","article-title":"Effectiveness of bortezomib in the treatment of thrombotic thrombocytopenic purpura: Case report","volume":"152","author":"Hern\u00e1ndez Lorente","year":"2019","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"10.1016\/j.tmrv.2022.09.001_bib0084","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jca.21710","article-title":"Survival of a Jehovah\u2019s Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature","volume":"34","author":"Baseri","year":"2019","journal-title":"J Clin Apher"},{"issue":"6","key":"10.1016\/j.tmrv.2022.09.001_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103213","article-title":"Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab","volume":"60","author":"Bavli","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"10.1016\/j.tmrv.2022.09.001_bib0086","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1097\/MPH.0000000000002026","article-title":"Successful treatment with bortezomib for refractory and complicated acquired thrombotic thrombocytopenic purpura in an adolescent girl","volume":"43","author":"Azapagasi","year":"2021","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:37Z","timestamp":1760138437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796322000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0887796322000426"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.09.001","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP)","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}